Article info

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Authors

  1. Correspondence to Dr John B Buse; jbuse{at}med.unc.edu
View Full Text

Citation

Buse JB, Bode BW, Mertens A for the PIONEER 7 investigators, et al
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Publication history

  • Received June 5, 2020
  • Revised October 21, 2020
  • Accepted November 2, 2020
  • First published December 14, 2020.
Online issue publication 
December 14, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.